<DOC>
	<DOCNO>NCT00515333</DOCNO>
	<brief_summary>The primary objective study investigate effect oral TRx0014 three dos ( 30 , 60 100 mg tid ) compare placebo cognitive ability patient mild moderate dementia Alzheimer type . Cognitive ability measure Alzheimer 's Disease Assessment Scale - cognitive subscale ( ADAS-cog ) . The primary evaluation make 24 week .</brief_summary>
	<brief_title>TRx0014 Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient may either sex must supervise carer competent ensure compliance medication willing participate complete various assessment . Patients must able give write informed consent participate study . Patients lack capacity consent may enter . Competent carer must available must provide write consent participation study . Clinical diagnosis dementia Alzheimer type determine Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criteria diagnosis Probable Alzheimer 's Disease determine National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion . Information support diagnosis include derive : abbreviate Cambridge Mental Disorders Elderly Examination ( short CAMDEX ) schedule , perform within six week prior baseline visit ( Visit 0 ) . Computerised tomography ( CT ) magnetic resonance imaging ( MRI ) , time limit previous scan . In centre conduct SPECT/PET scan part routine practice part study may use inform NINCDSADRDA diagnosis . Patient must mild moderate dementia determine : MiniMental State Examination ( MMSE ) value screen 10 26 inclusive . Clinical Dementia Rating ( CDR ) screen Stage 1 Stage 2 . Patient known sensitivity TRx0014 , similar agent excipients use . Screening blood sample show patient glucose6phosphate dehydrogenase deficiency . Patient known hereditary methaemoglobinaemia , know suffer attack acquire methaemoglobinaemia blood level methaemoglobin screen upper limit normal age laboratory . Patient significant impairment renal , hepatic haematological function age patient . Patient currently take antidementia drug ( e.g . memantine , cholinesterase inhibitor ) take within previous six week . It anticipate definite indication commencement license antidementia drug treatment within 24 week treatment period trial . Patient start take medication know effect mood cognition ( e.g . anticholinergic , hypnotic , sedative , anxiolytic , neuroleptic , antidepressant , antiepileptic ) within previous six week ; change dose medication within previous six week . Patient start take 'alternative therapy ' AD e.g . vitamin E , folic acid , hormone replacement therapy ( HRT ) , ginkgo biloba within previous six week ; change dose treatment within previous six week . Patient receive warfarin digitalis medication narrow margin effective dose toxic dose effective dose ineffective dose , subject would risk level elevate fell due interaction TRx0014 . Patients unlikely comply trial visit schedule trial medication . Significant intercurrent illness may compromise safety patient/validity data . Females potential childbearing use adequate contraception female breastfeed . Patients history alcohol and/or drug abuse , define meeting DSMIV criterion substance dependence . This apply alcohol and/or illicit drug , include cannabis within last six month . Patient participate clinical investigation medication device within previous three month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Dementia</keyword>
</DOC>